Vol. 85, Issue 4, 1421-1428, October 1998
Effect of urokinase on disseminated intravascular coagulation
Yvonne
Vasquez,
Charles H.
Williams, and
Robert M.
Hardaway
Departments of Anesthesiology, Biochemistry, and Surgery, Texas
Tech University Health Science Center, El Paso, Texas 79905
 |
ABSTRACT |
Our study
evaluated the possible therapeutic effect of urokinase in treating the
microthrombiotic effects of disseminated intravascular coagulation by
assisting the activation of endogenous plasminogen. Twenty-six pigs
were anesthetized, intubated, mechanically ventilated, and surgically
catheterized. Septic shock was induced in all 26 pigs by an intravenous
infusion of heat-killed Escherichia coli. The pigs were divided into two sets of
experiments: in experiment 2 (n = 14), one-half received an
intravenous dose of urokinase 1 h after heat-killed E. coli infusion and in experiment
3 (n = 12) one-half
received an intravenous bolus dose and a continuous drip of urokinase 2 h after heat-killed E. coli infusion.
The untreated pigs served as controls. Hemodynamic parameters, blood chemistries, and blood gases were analyzed. Urokinase given 1 h after
bacterial toxin infusion significantly restored blood flow, resulting
in an increase in cardiovascular and pulmonary function and improved
survival rate (43% control vs. 100% treated, 24-h experimental
period). Treatment given after 2 h showed some significant effect on
pulmonary function; however, within 10 h of E. coli infusion, mortality rates in control and treated
groups were 100 and 83%, respectively. Early administration of
urokinase after onset of disseminated intravascular coagulation
restored blood flow and helped resolve organ damage.
septic shock; heat-killed Escherichia
coli; swine
 |
INTRODUCTION |
DISSEMINATED INTRAVASCULAR COAGULATION (DIC) is
commonly reported in septic shock. How DIC is initiated is not clearly
understood. It has been postulated that the presence of endotoxin
activates the coagulation system, resulting in a marked increase in
thrombin and fibrin production (2). Endotoxin may trigger the
coagulation system by causing damage to the endothelium (20)
and/or by releasing procoagulant materials (2). Fibrinolysis is
inhibited during sepsis by elevated levels of plasminogen-activator
inhibitors and may contribute to the pathogenesis of DIC (3, 19).
Subsequent microvascular thrombosis and occlusion may also lead to the
development of multiple-organ failure (6, 10, 11). The treatment of thrombosis can be approached by lysing blood clots via the intravenous infusion of pharmacological plasminogen activators. Studies have shown
urokinase and tissue-type plasminogen activator to be useful thrombolytic agents in animal models (12, 13).
Urokinase is a proteolytic enzyme produced by the kidney and found in
urine. A low-molecular-weight urokinase, which was isolated from human
kidney cell culture, was obtained from Abbott Laboratories, Chicago, IL
(Abbokinase). Urokinase acts on the endogenous fibrinolytic system by
converting plasminogen to plasmin, which, in return, degrades fibrin
clots (9). Based on the therapeutic principle of urokinase, we
investigated whether this thrombolytic agent would be able to treat the
microthrombiotic effects of DIC by lysing microclots and restoring
circulation, thus minimizing organ failure and mortality in pigs
infused with heat-killed Escherichia coli.
 |
MATERIALS AND METHODS |
Animal preparation. This study was
approved by the Animal Care Committee of Texas Tech University Health
Science Center. Twenty-six commercial pigs weighing 29-45 kg were
anesthetized with ketamine hydrochloride (10 mg/kg im), acepromazine
(0.2 mg/kg), xylazine (1 mg/kg), and pentothal (3 mg/kg iv), and they
continued to receive a dilute dose of pentothal (0.5 mg) as needed. The
animals were intubated and mechanically ventilated (North America
Drager; Telford, PA) with 30% oxygen-70% room air. The left carotid
artery was catheterized for blood pressure monitoring, blood sampling,
and fluid administration. A pressure-sensor catheter (Millar; Houston, TX) was also inserted into the left carotid artery and guided into the
left ventricular cavity. The left jugular vein was
cannulated for a balloon-tipped pulmonary artery catheter (Opticath;
Abbott, Mountain View, CA), which was floated into the pulmonary
artery, and the following hemodynamic and physiological parameters were recorded: central venous pressure (CVP), mean pulmonary arterial pressure (MPAP), mean pulmonary capillary wedge pressure
(MPCWP), and cardiac output (CO) by thermodilution (9520A; Edwards
Laboratories; Santa Ana, CA); core temperature via the thermocouple;
and venous oxyhemoglobin (HbO2)
saturation via an oximeter (OS/880, Oximetrix; Mountain View, CA). A
second catheter was also slipped into the left jugular vein for blood
sampling and fluid administration. All catheters were connected to a
pressure transducer (1290A; Hewlett-Packard; Waltham, MA) and monitored
via a multichannel recorder (7758A; Hewlett-Packard). Thermodilution CO
was determined by injecting 10 cm3
of iced dextrose via a central venous line. This procedure was performed in duplicates at 0.5-h intervals. End-expiratory
CO2 was measured with a capnograph
(7050, Marquette Electronics, Milwaukee, WI). A cutaneous three-lead
electrocardiograph was used, and lead II was monitored (78432A monitor
and 78172A recorder; Hewlett-Packard). The urinary bladder was
catheterized for urine output. Body temperature was monitored via a
rectal thermistor (43TA Tele-Thermometer; Yellow Spring
Instruments; Yellow Springs, OH). The femoral vein was probed
for blood flow rate and was monitored on a meter (T101 Ultrasonic
Bloodflow Meter; Transonic Systems, Ithaca, NY). Blood volume and CVP
were maintained at normal levels by an intravenous drip of isotonic
saline (0.9% sodium chloride). Blood was analyzed for arterial and
mixed venous blood gases, fibrin degradation products, fibrinogen,
activated partial thromboplastin time, prothrombin time, platelet
count, mean corpuscular volume, mean corpuscular hemoglobin,
mean corpuscular hemoglobin concentration, hematocrit, hemoglobin, red
blood cell count, white blood cell count, glutamic-pyruvic transaminase
(GPT), lactic acid, blood urea nitrogen (BUN), creatinine, BUN/creatinine ratio, and Lee-White clot time. Blood gases were measured by CO-oximetry analysis (Radiometer America, Westlake, OH),
and blood chemistries were analyzed at Thomason General Hospital Laboratory (El Paso, TX).
Heat-killed E. coli preparation.
E. coli (EC, serotype 078:H11;
American Type Culture Collection, Rockville, MD) were grown in Lennox L
broth at 37°C in a shaking water bath for 24 h. Organisms were
washed three times and resuspended in isotonic saline. Inocula were
adjusted to 2 × 1010/ml by a
hemacytometer and then killed by boiling for 30 min. After sterility
(complete killing) verification, they were stored at
70°C
until needed. The dose of E. coli was
selected to cause a lethal effect on the lung and death at ~8 h or
after the animal was removed from the ventilator.
Experimental protocol. After catheter
insertions, animals were stabilized for 30 min, and then baseline
measurements were recorded. Control measurements were recorded 1 h
after stabilization. All pigs were then injected with 2 ml/37.5 kg of
heat-killed E. coli in 20 ml isotonic
saline over a 20-min period, with the use of a mechanical injector
(341A; Sage Instruments; Cambridge, MA). The pigs were divided into two
sets of experiments: experiment 2 (n = 14) and
experiment 3 (n = 12). Seven of the
fourteen pigs in experiment 2 were
given an intravenous bolus dose of 250,000 U/37.5 kg of urokinase
(Abbokinase, Abbott Laboratories) diluted in 20 ml of isotonic saline
over a 20-min period 1 h after killed E. coli infusion. In experiment
3, 6 of the 12 pigs received an intravenous bolus dose
of 250,000 U/37.5 kg of urokinase diluted in 20 ml of isotonic saline
over a 20-min period 2 h after killed E. coli infusion. This was followed by a continuous
infusion of 2,000 U · pound
1 · h
1
of urokinase at a rate of 15 ml/h for 12 h. The untreated pigs in both
experiments served as controls. Hemodynamic parameters were taken
immediately after E. coli infusion and
continued to be recorded at 0.5-h intervals for 7 h. The mechanical
ventilator, catheters, and anesthesia were discontinued at the end of
the 7-h period. The animals were placed in a cage for observation and
allowed to recover spontaneously. Animals alive after 24 h were counted
as survivors and killed by lethal injection of pentobarbital sodium.
Blood chemistries and blood gases were measured at baseline; 1 h
immediately after killed E. coli
infusion (IAC); 1 h (experiment 2)
and 2 h (experiment
3) after killed E. coli for control pigs or immediately after urokinase
for treated pigs; and at 5, 8, 12, 14.5, 18.5, 22.5, and 24 h after
killed E. coli infusion. A postmortem
examination for gross and microscopic pathology was performed on all
animals. Tissues were fixed in 3% glutaraldehyde and postfixed in 1%
osmium tetroxide for transmission electron microscopy. The experiment
was terminated after 24 h because most endotoxin studies have used this
as an end point.
Calculations. The following
hemodynamic and respiratory parameters were derived by using these
standard equations
where
AP is arterial pressure
where
HR is heart rate
(Used
body weight rather then surface area for pig work)
where
PCWP is pulmonary capillary wedge pressure.
Statistical analysis. All values are
means ± SE. Comparisons among groups were made by split-plot test
(SAS program). Significance was accepted for
P < 0.05.
 |
RESULTS |
Mortality rate. In
experiment 2, four out of seven
control pigs (57%) died soon after the mechanical ventilator was
removed, whereas all treated pigs (100%) survived the full 24-h
experimental period. In experiment 3,
all control pigs (100%) died within 10 h after infusion of killed
E. coli, and five out of six treated pigs (83%) died within 10 h.
Necropsy and histological findings. At
necropsy, the lungs of all control pigs were hemorrhagic, congested,
cyanotic, and edematous with involvement of most of both lungs. In some
cases, the stomach and gut showed congested and hemorrhagic area. Liver and spleen often showed congestion. Histopathology reports showed lung
atelectasis, focal accumulation of neutrophils in the aveolar spaces,
proteinaceous alveolar edema, scattered bronchi filled with
neutrophils, and swelling and proliferation of alveolar septal cells.
The spleen had congestion of red pulp and lymphocytic necrosis of the
germinal centers with karyorrhexis and pyknosis. The liver had
lymphocytes and eosinophils in the portal tracts, hepatocellular swelling and cytoplasmic vacuolation, paraportal edema, and early bile
duct hyperplasia. The pancreas had homogeneous eosinophilic fluid in
the interlobular spaces, necrosis of acinar cells (pyknosis), few
scattered neutrophils, loss of zymogen granules, and scattered acinar
cells with clear cytoplasmic vacuolation. The stomach had hyperemia,
necrosis, and hemorrhage. The kidney had interstitial accumulation of
lymphocytes, proteinuria, and congestion of glomeruli. Heart, duodenum,
brain, and skeletal muscle showed no significant lesions. Treated pigs
in both experiment showed mild lesions; however, lesions in the animals
from experiment 3 were greater compared with those from experiment 2.
DIC parameter changes. The onset of
DIC was indicated by a fall in fibrinogen levels, fall in platelet
count, and appearance of fibrin-degradation products (Table
1). In
experiments 2 and 3, fibrinogen and fibrin-degradation
product levels showed no significant difference between control and
treated pig groups. Platelet levels were lower in the treated group 8 h
after killed E. coli
infusion in experiment 2. No
significant difference between groups was noted in
experiment 3. Urokinase treatment did
not correct DIC changes in either experiment.
Systemic hemodynamics. The intravenous
injection of killed E. coli resulted
in a fall in MAP, CI, CPP, LVSWI, SVRI, SV, and CO in both experiments.
No significant difference in MAP and CI was noted between control and
treated pig groups in either experiment 2 or 3. CPP, LVSWI,
and SVRI, levels were higher in the treated group 2 h after killed
E. coli infusion in
experiment 2 (P < 0.05), and in
experiment 3 no significant difference
was noted between groups (Fig. 1). SV tried
to recover to baseline levels after urokinase treatment, whereas
control group levels continued to drop
(P < 0.05) in
experiment 2 (Fig.
2A). SV
in experiment 3 showed no attempt for
recovery in the treated group (Fig.
2B). CO also tried to recover in
treated and control groups, but treated levels in
experiment 2 and control levels in
experiment 3 decreased (P < 0.05) 2 h after
killed E. coli infusion for the
remainder of both experiments (Fig. 2,
C and
D). HR increased 2 h after killed
E. coli infusion, which persisted
until the end of both experiments (Fig. 2,
E and
F). MCVP changes were inconsistent in control and treated groups for both experiments.

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 1.
Coronary perfusion pressure (CPP;
A and
B), left ventricular stroke work
index (LVSWI; C and
D), and systemic vascular resistance
index (SVRI; E and
F) during killed
Escherichia coli infusion. All pigs
were intravenously injected with 2 ml of killed E. coli (2 × 1010 cells/ml) at a rate of 20 ml/min over a 20-min period. Urokinase treatment was delayed in
experiment 2 (A,
C, and
E) and experiment
3 (B,
D, and
F) for 1 and 2 h, respectively. Data
are means ± SE. IAC, immediately after killed E. coli infusion.
* P < 0.05 from baseline
(Base);
+ P < 0.001 from baseline; and
# P < 0.05 between groups.
|
|

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 2.
Stroke volume (SV; A
and B), cardiac output (CO;
C and
D), and heart rate (HR;
E and
F) during killed E. coli infusion. All pigs were intravenously injected
with 2 ml of killed E. coli (2 × 1010 cells/ml) at a rate of 20 ml/min over a 20-min period. Urokinase treatment was delayed in
experiment 2 (A,
C, and
E) and experiment
3 (B,
D, and
F) for 1 and 2 h, respectively.
Values are means ± SE. * P < 0.05 from baseline;
+ P < 0.001 from baseline; and
# P < 0.05 between groups.
|
|
Pulmonary hemodynamics. MPAP, PVR, and
RVSWI peaked immediately after the onset of killed E. coli infusion and then dropped but remained above
baseline levels for the remainder of both experiments. After
the administration of urokinase, MPAP levels were lower (P < 0.05) in the treated group at 3 h compared with the control group in experiment
2 (Fig. 3,
A and
B). In experiment
3, a difference (P < 0.05) in MPAP levels was noted until 6 h after E. coli infusion. PVR showed no significant difference
between groups for experiment 2;
however, a significant difference was noted between groups after the
administration of urokinase in experiment
3 (Fig. 3, C and
D). RVSWI levels were significantly
lower 2.5 h after killed E. coli
infusion in the treated group for experiment
2. Experiment 3 showed
no difference between groups for RVSWI levels (Fig. 3, E and
F). MPCWP changes were inconsistent
in control and treated groups for both experiments.

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 3.
Mean pulmonary artery pressure (MPAP;
A and
B), pulmonary vascular resistance
(PVR; C and
D), and right ventricular stroke
work index (RVSWI; E and
F) during killed E. coli infusion. All pigs were intravenously injected
with 2 ml of killed E. coli (2 × 1010 cells/ml) at a rate of 20 ml/min over a 20-min period. Urokinase treatment was delayed in
experiment 2 (A,
C, and
E) and experiment
3 (B,
D, and
F) for 1 and 2 h, respectively. Data
are means ± SE. * P < 0.05 from baseline;
+ P < 0.001 from baseline; and
# P < 0.05 between groups.
|
|
Blood gases. A progressive fall in
arterial oxygen tension (PaO2) was
observed after killed E. coli infusion
in both pig groups. In experiment 2,
PaO2 dropped
(P < 0.01) from 366 Torr at baseline to 39.8 Torr at 8 h in the control group
and from 316.5 Torr at baseline to 104.1 Torr at 8 h in the treated
group. Both groups maintained minimal levels for the remainder of the
experiment (Fig.
4A). In
experiment 3,
PaO2 dropped
(P < 0.01) from 327 Torr at baseline
to 28.1 Torr at 6-8 h in the control group and from 315.3 Torr at
baseline to 37.1 Torr at 6-8 h in the treated group (Fig.
4B). The marked fall, observed in
both pig groups and experiments, in PaO2
at 8 h was due to the discontinuation of oxygen supplementation at 7 h.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 4.
Arterial oxygen tension
(PaO2;
A and
B), arterial oxyhemoglobin
(aHbO2;
C and
D), and arterial hydrogen ion
concentration (pH; E and
F) during killed E. coli infusion. All pigs were intravenously injected
with 2 ml of killed E. coli (2 × 1010 cells/ml) at a rate
of 20 ml/min over a 20-min period. Urokinase treatment was delayed in
experiment 2 (A,
C, and
E) and experiment
3 (B,
D, and
F) for 1 and 2 h, respectively. Data
are means ± SE. * P < 0.05 from baseline;
+ P < 0.001 from baseline; and
# P < 0.05 between groups.
|
|
Arterial HbO2 levels were
maintained at baseline levels for the 7-h experimental duration on
the mechanical ventilator but rapidly dropped after discontinuation of
oxygen. In experiment 2, arterial
HbO2 dropped
(P < 0.01) from 97.9% at baseline
to 37.6% at 8 h in the control group and from 97.9% at
baseline to 67.7% at 8 h in the treated group. Both groups remained
below baseline levels for the duration of the experiment
(Fig. 4C). In
experiment 3, arterial
HbO2 dropped
(P < 0.01) from 97.9% at baseline
to 28% at 6-8 h in the control group and from 98.4% at baseline
to 43.9% at 6-8 h in the treated group (Fig.
4D).
In comparing control and treated groups for experiment
2, a progressive decrease in arterial pH (from
7.48 to 7.32 and from 7.48 to 7.34, respectively,
P < 0.05) was observed
during the 5-h period subsequent to killed
E. coli infusion (Fig.
4E). Arterial pH levels in both
groups then returned to baseline levels by the conclusion of the
experiment. In experiment 3, arterial
pH also dropped (P < 0.01) from 7.4 at baseline to 7.2 at 6-8 h in the control group and from 7.5 at
baseline to 7.2 at 6-8 h in the treated group (Fig.
4F). Supplemental oxygen was
discontinued at 7 h.
Blood chemistries. Creatinine, BUN,
and GPT levels were monitored as indicator of renal failure,
impaired kidney function, and liver malfunction, respectively.
Creatinine, BUN, and GPT levels had a minimal change, and no
significant difference was noted between control and treated pig groups
in experiment 2 and 3.
 |
DISCUSSION |
The administration of heat-killed E. coli resulted in changes typical of severe septic
shock, with DIC changes characterized by a fall in fibrinogen levels,
fall in platelet count, and appearance of fibrin-degradation products.
Septic shock changes included a fall in MAP, a rise in mean pulmonary
pressure, a fall in CO, and an increase in HR. These DIC (2, 11, 20)
and septic-shock (1, 16) changes are in agreement with previous
experimental reports in patients; however, the DIC value changes in our
swine model are moderate compared with human value changes.
Using this swine model of septic shock, we found that a bolus dose of
urokinase administered 1 h after killed E. coli infusion improved cardiovascular and pulmonary
function. Pulmonary hypertension and vasoconstriction are some of the
initial responses to killed E. coli. During the second phase, which occurs at ~3
h, urokinase reduced pulmonary hypertension but not PVR. Low CPP,
LVSWI, and SVRI levels were improved 1 h after urokinase treatment
(P < 0.05), and several attempts of
recovery were noted for SV and CO levels. RVSWI levels were lowered 1.5 h (P < 0.05) after urokinase
administration and remained below control pig levels for the remainder
of the experiment. Systemic hypotension was not affected by urokinase.
Urokinase administered in a bolus dose, followed by a continuous drip,
2 h after killed E. coli infusion
improved pulmonary performance but did not have much of an effect on
cardiovascular dysfunction. The second phase of pulmonary hypertension
and vasoconstriction was reduced by urokinase treatment. CO remained at
normal levels after treatment and stayed above control pigs levels
until the end of the experiment. Urokinase had no effect on systemic
hypotension.
In a previous experiment (7), we also found that in swine challenged
with killed E. coli and treated 20 min
later with a bolus dose of urokinase cardiovascular and pulmonary
function was favorably affected. High MPAP levels were returned to
normal after urokinase treatment.
After the mechanical ventilator was discontinued (7 h after killed
E. coli infusion), arterial blood
gases were affected. Significant changes were observed: a fall in
oxygen tension and HbO2 and a rise
in hydrogen ion concentration. Pigs treated 20 min and 1 h after killed
E. coli infusion maintained higher
levels of oxygen tension and HbO2,
and hydrogen ion concentrations returned to normal values. All pigs
treated 2 h after killed E. coli
infusion died shortly after ventilator removal.
We also found that urokinase administration during swine septic shock
prolonged survival. In our present study, all treated pigs in
experiment 2 (1-h lapse before
urokinase treatment) survived the 24-h experimental period, whereas
only 43% of the control pigs lived for 24 h. In
experiment 3 (2-h lapse before
urokinase treatment), all control pigs died within 10 h of killed
E. coli infusion, and 83% of treated
pigs died within 10 h. Our previous study (20-min lapse before
urokinase treatment) (8) showed a 100% survival rate in
treated pigs for the 24-h experimental duration, and 88% of the
control pigs died before 24 h.
Other thrombolytic agents, such as streptokinase (17) and tissue-type
plasminogen activator (14), have also improved survival in endotoxemic
animals. Heparin (18) has been shown to prevent organ dysfunctions
associated with sepsis in rabbits, and saruplase (15), a recombinant
single-chain urokinase-type plasminogen activator, is able to dissolve
microthrombosis associated with DIC in endotoxemic rats. The
aforementioned thrombolytic therapies have either been administered as
a pretreatment or simultaneously with endotoxin infusion. Patient
reports have shown that the administration of urokinase is successful
in the treatment of pulmonary thromboembolism (4, 5).
Our previous study (8) in combination with the present
study suggest that the beneficial effects of urokinase on survival may
depend on how early the treatment is administered after the onset of
DIC. Subsequent microvascular thrombosis and occlusion lead to impeded
blood flow, tissue hypoxia, and microinfarction in such vital organs as
the liver, kidneys, and lung (8). Microinfarction would progressively
impair function and ultimately lead to organ failure. If microclots are
lysed shortly after their formation, damage is kept to a minimum. The
critical point in which microinfarction leading to organ failure is
irreversible seems to be within 2 h after killed E. coli infusion in pigs. Early administration of
urokinase may be of benefit in restoring blood flow and helping resolve
organ damage.
 |
ACKNOWLEDGEMENTS |
We thank Abbott Laboratories, Chicago, IL, for the generous gift of
urokinase and Thomason General Hospital, El Paso, TX, for the loan of
the CO-oximetry analyzer.
 |
FOOTNOTES |
Microscopic examination of all tissues was carried out by Texas
Veterinary Medical Diagnostic Laboratory System, College Station, TX.
Blood chemistries were analyzed by Thomason General Hospital Laboratory, El Paso, TX.
This work was presented in abstract form at the Experimental Biology
'98 Meeting, San Francisco, CA, on April 22, 1998 (Abstract no. 5733).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests: C. H. Williams, Dept. of
Anesthesiology/Biochemistry, Texas Tech Univ. Health Science Center,
4800 Alberta Ave., El Paso, TX 79905.
Received 30 January 1998; accepted in final form 12 June 1998.
 |
REFERENCES |
1.
Baue, A. E.
Physiology of shock and injury.
In: Shock and Resuscitation, edited by E. R. Geler. New York: McGraw-Hill, 1993, p. 67-125.
2.
Bick, R. L.
Disseminated intravascular coagulation.
Hematol. Oncol. Clin. North Am.
6:
1259-1285,
1992[Medline].
3.
Bone, R. C.
Modulators of coagulation: a critical appraisal of their role in sepsis.
Arch. Intern. Med.
152:
1381-1389,
1992[Abstract].
4.
Bottiger, B. W.,
S. M. Reim,
G. Diezel,
H. Bohrer,
and
E. Martin.
High-dose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism.
Chest
106:
1281-1283,
1994[Abstract/Free Full Text].
5.
Gonzalez-Juanatey, J. R.,
L. Valdes,
A. Amaro,
C. Iglesias,
D. Alvarez,
J. M. Garcia Acuna,
and
M. G. de la Pena.
Treatment of massive pulmonary thromboembolism with low intrapulmonary dosages of urokinase. Short-term angiographic and hemodynamic evolution.
Chest
102:
341-346,
1992[Abstract/Free Full Text].
6.
Hardaway, R. M.
Organ failure and disseminated intravascular coagulation.
In: Microcirculation in Circulatory Disorders, edited by H. Manabe,
B. W. Zweifach,
and K. Messmer. Tokyo: Springer-Verlag, 1988, p. 117-124.
7.
Hardaway, R. M.
A new look at disseminated intravascular coagulation.
ER Reports
2:
37-40,
1981.
8.
Hardaway, R. M.,
C. H. Williams,
and
Y. Sun.
A new approach to the treatment of experimental septic shock.
J. Surg. Res.
61:
311-316,
1996[Medline].
9.
Harke, H.,
and
S. Rahman.
The utilization of drugs in shock treatment.
In: Shock: the Reversible Stage of Dying, edited by R. M. Hardaway. Littleton, MA: PSG Publishing, 1988, p. 516-529.
10.
Hinshaw, L. B.
Sepsis/septic shock: participation of the microcirculation: an abbreviated review.
Crit. Care Med.
24:
1072-1078,
1996[Medline].
11.
Johnson, P. C.
Disseminated intravascular coagulation.
In: Multiple System Organ Failure, edited by D. E. Fry. St. Louis, MO: Mosby, 1992, p. 291-299.
12.
Korninger, C.,
O. Matsuo,
R. Suy,
J. M. Stasen,
and
D. Collen.
Thrombolysis with human extrinsic plasminogen activator in dogs with femoral vein thrombosis.
J. Clin. Invest.
69:
573-580,
1982.
13.
Matsuo, O.,
D. C. Rijken,
and
D. Collen.
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus.
Nature
291:
590-591,
1981[Medline].
14.
Paloma, M. J.,
J. A. Paramo,
and
E. Rocha.
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs. urokinase on PAI generation, fibrin deposit and mortality.
Thromb. Haemost.
74:
1578-1582,
1995[Medline].
15.
Schneider, J.
Fibrin-specific lysis of microthrombosis in endotoxemic rats by saruplase.
Thromb. Res.
72:
71-82,
1993[Medline].
16.
Siegel, J. H.,
F. B. Cerra,
B. Coleman,
I. Giovanni,
M. Shetye,
J. R. Border,
and
R. H. McMenamy.
Physiologic and metabolic corrections in human sepsis.
Surgery
86:
163,
1979[Medline].
17.
Smith, E. F.,
L. B. Kinter,
M. Jugus,
and
R. Zeid.
Effect of the thrombolytic agent, streptokinase, on the responses to endotoxemia in conscious rates.
Circ. Shock
25:
85-94,
1988[Medline].
18.
Tanaka, T.,
T. Tsujinaka,
J. Kambayashi,
M. Higashiyama,
M. Yokota,
M. Sakon,
and
T. Mori.
The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model.
Thromb. Res.
60:
321-330,
1990[Medline].
19.
Thijs, L. G.,
J. P. de Boer,
M. C. M. de Groot,
and
C. E. Hack.
Coagulation disorders in septic shock.
Intensive Care Med.
19:
S8-S15,
1993.
20.
Wu, K. K.
Disseminated intravascular coagulation.
In: Pathophysiology and Management of Thromboembolic Disorders, edited by K. K. Wu. Littleton, MA: PSG Publishing, 1984, p. 247-266.
J APPL PHYSIOL 85(4):1421-1428
8570-7587/98 $5.00
Copyright © 1998 the American Physiological Society